Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195

M. Tanimoto, D. A. Scheinberg, C. Cordon-Cardo, D. Huie, B. D. Clarkson, L. J. Old

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

A mouse monoclonal IgG2a antibody, M195, with reactivity restricted to early myeloid cells, acute non-lymphoid leukemia cells (ANLL), and monocytic cells is described. The antibody was derived from a mouse immunized with live human leukemic myeloblasts. Specificity of binding of mAb M195 was determined by protein-A red blood cell rosetting assays, immunoabsorption, radioimmunoassays with iodine-125 labeled M195 IgG and F(Ab)'2, and complement cytotoxicity with live human cells and cell lines representing a broad range of lineages and tissues. Antigen expression was restricted to myeloid and monocytic leukemia cell lines and a fraction of mature adherent monocytes. Mature myeloid cells, T and B cells, erythrocytes, and platelets were negative. The antigen was not expressed on adult human tissues in immunoperoxidase and immunofluorescence assays. Blocking antigen was not found in the serum of patients with ANLL. Ten thousand sites per cell were expressed on myeloid or monocytic leukemia cell lines and 5000 sites per cell on mature monocytes. M195 IgG bound to its antigen target with an avidity of 3x109 liters/mol and induced rapid modulation of the antigen. M195 IgG was able to effectively kill cells with rabbit or guinea pig complement, but not human complement. The antibody did not mediate antibody dependent cellular cytotoxicity. The molecular nature of the target antigen remains unknown but it appears to be carried on the CD33 protein p67. Because of its restricted distribution on myelomonocytic cells, mAb M195 may be useful in studying myeloid differentiation, in the clinical diagnosis of ANLL, in purging of bone marrow of ANLL, and/or in monoclonal antibody therapy in vivo.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
JournalLeukemia
Volume3
Issue number5
Publication statusPublished - 1989
Externally publishedYes

Fingerprint

Myeloid Cells
Surface Antigens
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Antigens
Immunoglobulin G
Cell Line
Antibodies
Monocytes
Bone Marrow Purging
Erythrocytes
Complement C2
monoclonal antibody M195
Granulocyte Precursor Cells
Myeloid Leukemia
Staphylococcal Protein A
Iodine
Radioimmunoassay
Fluorescent Antibody Technique
Guinea Pigs
Leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Tanimoto, M., Scheinberg, D. A., Cordon-Cardo, C., Huie, D., Clarkson, B. D., & Old, L. J. (1989). Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia, 3(5), 339-348.

Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. / Tanimoto, M.; Scheinberg, D. A.; Cordon-Cardo, C.; Huie, D.; Clarkson, B. D.; Old, L. J.

In: Leukemia, Vol. 3, No. 5, 1989, p. 339-348.

Research output: Contribution to journalArticle

Tanimoto, M, Scheinberg, DA, Cordon-Cardo, C, Huie, D, Clarkson, BD & Old, LJ 1989, 'Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195', Leukemia, vol. 3, no. 5, pp. 339-348.
Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia. 1989;3(5):339-348.
Tanimoto, M. ; Scheinberg, D. A. ; Cordon-Cardo, C. ; Huie, D. ; Clarkson, B. D. ; Old, L. J. / Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. In: Leukemia. 1989 ; Vol. 3, No. 5. pp. 339-348.
@article{b98df290ffca47e2a80ba9a104ef4248,
title = "Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195",
abstract = "A mouse monoclonal IgG2a antibody, M195, with reactivity restricted to early myeloid cells, acute non-lymphoid leukemia cells (ANLL), and monocytic cells is described. The antibody was derived from a mouse immunized with live human leukemic myeloblasts. Specificity of binding of mAb M195 was determined by protein-A red blood cell rosetting assays, immunoabsorption, radioimmunoassays with iodine-125 labeled M195 IgG and F(Ab)'2, and complement cytotoxicity with live human cells and cell lines representing a broad range of lineages and tissues. Antigen expression was restricted to myeloid and monocytic leukemia cell lines and a fraction of mature adherent monocytes. Mature myeloid cells, T and B cells, erythrocytes, and platelets were negative. The antigen was not expressed on adult human tissues in immunoperoxidase and immunofluorescence assays. Blocking antigen was not found in the serum of patients with ANLL. Ten thousand sites per cell were expressed on myeloid or monocytic leukemia cell lines and 5000 sites per cell on mature monocytes. M195 IgG bound to its antigen target with an avidity of 3x109 liters/mol and induced rapid modulation of the antigen. M195 IgG was able to effectively kill cells with rabbit or guinea pig complement, but not human complement. The antibody did not mediate antibody dependent cellular cytotoxicity. The molecular nature of the target antigen remains unknown but it appears to be carried on the CD33 protein p67. Because of its restricted distribution on myelomonocytic cells, mAb M195 may be useful in studying myeloid differentiation, in the clinical diagnosis of ANLL, in purging of bone marrow of ANLL, and/or in monoclonal antibody therapy in vivo.",
author = "M. Tanimoto and Scheinberg, {D. A.} and C. Cordon-Cardo and D. Huie and Clarkson, {B. D.} and Old, {L. J.}",
year = "1989",
language = "English",
volume = "3",
pages = "339--348",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195

AU - Tanimoto, M.

AU - Scheinberg, D. A.

AU - Cordon-Cardo, C.

AU - Huie, D.

AU - Clarkson, B. D.

AU - Old, L. J.

PY - 1989

Y1 - 1989

N2 - A mouse monoclonal IgG2a antibody, M195, with reactivity restricted to early myeloid cells, acute non-lymphoid leukemia cells (ANLL), and monocytic cells is described. The antibody was derived from a mouse immunized with live human leukemic myeloblasts. Specificity of binding of mAb M195 was determined by protein-A red blood cell rosetting assays, immunoabsorption, radioimmunoassays with iodine-125 labeled M195 IgG and F(Ab)'2, and complement cytotoxicity with live human cells and cell lines representing a broad range of lineages and tissues. Antigen expression was restricted to myeloid and monocytic leukemia cell lines and a fraction of mature adherent monocytes. Mature myeloid cells, T and B cells, erythrocytes, and platelets were negative. The antigen was not expressed on adult human tissues in immunoperoxidase and immunofluorescence assays. Blocking antigen was not found in the serum of patients with ANLL. Ten thousand sites per cell were expressed on myeloid or monocytic leukemia cell lines and 5000 sites per cell on mature monocytes. M195 IgG bound to its antigen target with an avidity of 3x109 liters/mol and induced rapid modulation of the antigen. M195 IgG was able to effectively kill cells with rabbit or guinea pig complement, but not human complement. The antibody did not mediate antibody dependent cellular cytotoxicity. The molecular nature of the target antigen remains unknown but it appears to be carried on the CD33 protein p67. Because of its restricted distribution on myelomonocytic cells, mAb M195 may be useful in studying myeloid differentiation, in the clinical diagnosis of ANLL, in purging of bone marrow of ANLL, and/or in monoclonal antibody therapy in vivo.

AB - A mouse monoclonal IgG2a antibody, M195, with reactivity restricted to early myeloid cells, acute non-lymphoid leukemia cells (ANLL), and monocytic cells is described. The antibody was derived from a mouse immunized with live human leukemic myeloblasts. Specificity of binding of mAb M195 was determined by protein-A red blood cell rosetting assays, immunoabsorption, radioimmunoassays with iodine-125 labeled M195 IgG and F(Ab)'2, and complement cytotoxicity with live human cells and cell lines representing a broad range of lineages and tissues. Antigen expression was restricted to myeloid and monocytic leukemia cell lines and a fraction of mature adherent monocytes. Mature myeloid cells, T and B cells, erythrocytes, and platelets were negative. The antigen was not expressed on adult human tissues in immunoperoxidase and immunofluorescence assays. Blocking antigen was not found in the serum of patients with ANLL. Ten thousand sites per cell were expressed on myeloid or monocytic leukemia cell lines and 5000 sites per cell on mature monocytes. M195 IgG bound to its antigen target with an avidity of 3x109 liters/mol and induced rapid modulation of the antigen. M195 IgG was able to effectively kill cells with rabbit or guinea pig complement, but not human complement. The antibody did not mediate antibody dependent cellular cytotoxicity. The molecular nature of the target antigen remains unknown but it appears to be carried on the CD33 protein p67. Because of its restricted distribution on myelomonocytic cells, mAb M195 may be useful in studying myeloid differentiation, in the clinical diagnosis of ANLL, in purging of bone marrow of ANLL, and/or in monoclonal antibody therapy in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0024509637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024509637&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 339

EP - 348

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -